VA-MARS,-INCORPORATED
Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland. With approximately 140 Associates, Cerba Vet provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
Headquartered in Lyon, France, ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests globally for diagnosing diseases in pets, as well as supporting scientific initiatives to preserve biodiversity.
Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.
Nefertiti Greene, President, Mars Science & Diagnostics, said: “We are excited about this opportunity and look forward to finalizing discussions and working together with the Cerba Vet and ANTAGENE teams to enhance our reach and drive R&D to help veterinarians improve animal health outcomes, delivering A BETTER WORLD FOR PETS™.”
Emmanuel Ligner, CEO, Cerba HealthCare, added: “We are proud of what the teams have accomplished over the years to lead innovation and enhance services for the entire veterinarian community. We believe that Mars Science & Diagnostics is the right investor for Cerba Vet and ANTAGENE and would be able to support the long-term development and growth of these businesses. Mars Science & Diagnostics is known for its commitment to science and innovation, strong partnerships with veterinary professionals and purpose-driven culture.”
The contemplated acquisition remains subject to the information and/or consultation of the employees and employee representative bodies of Cerba Vet and ANTAGENE. Completion of such contemplated acquisition would also be subject to customary closing requirements following the execution of definitive transaction agreements.
About Mars, Incorporated
For more than a century, Mars, Incorporated has been driven by the belief that the world we want tomorrow starts with how we do business today. This common purpose unites our 140,000+ Associates. It is at the center of who we are as a global, family-owned business, and it fuels how we are transforming, innovating, and evolving to make a positive impact on the world.
Every year, our diverse and expanding portfolio of quality confectionery, food, and pet care products and services delights millions of people and supports millions of pets. With more than $47 billion in annual sales, we produce some of the world’s best-loved brands including CESAR®, Ben’s Original™, PEDIGREE®, ROYAL CANIN®, Cocoavia®, DOVE®, EXTRA®, KIND®, M&M’s®, SNICKERS® and WHISKAS®. We are creating a better world for pets through nutrition, breakthrough programs in diagnostics, wearable health monitoring, DNA testing, pet welfare and comprehensive veterinary care with AniCura, BANFIELD™, BLUEPEARL™, Linnaeus and VCA™. Mars Science & Diagnostics is a division of Mars Petcare dedicated to one purpose: A BETTER WORLD FOR PETS. Science & Diagnostics brings together the power of leading science with expertise across diagnostics, data, and technology to change outcomes in pet health.
We know we can only be truly successful if our partners and the communities in which we operate prosper as well. The Mars Five Principles – Quality, Responsibility, Mutuality, Efficiency and Freedom – inspire our Associates to take action every day to help create a world tomorrow in which the planet, its people and pets can thrive.
For more information about Mars, please visit www.mars.com. Join us on Facebook, Twitter, Instagram, LinkedIn and YouTube.
About Mars Science & Diagnostics
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business Antech spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90 reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503904264/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 19:00:00 CEST | Press release
PIF joins inaugural FIFA Club World Cup™ ahead of kick-off on June 14 in Miami The partnership expands PIF’s global footprint in sports and reflects a shared commitment with FIFA to fuel growth and engagement in football FIFA Club World Cup 2025™ will make history, redefining club football and bringing 32 of the world’s best clubs together for the first time PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football c
Orange Logic Appoints Ben Colenso as Managing Director, EMEA5.6.2025 18:41:00 CEST | Press release
Strategic hire underscores company’s growth and commitment to the region Orange Logic, the leader in digital asset management and content orchestration, today announced the appointment of Ben Colenso as Managing Director for EMEA. Based in the UK, Colenso will spearhead Orange Logic’s regional strategy, customer enablement, and market expansion efforts, as the company accelerates its global footprint. Colenso brings 20 years of experience in technology and media production, having most recently led the technology strategy for Hogarth, WPP’s content experience company. Known for solving complex problems for some of the world’s most iconic brands with his customer-centric approach, Colenso will play a critical role in strengthening Orange Logic’s presence and partnerships across EMEA which span customers such as ITV, Pearson, GSK, Ubisoft and Tourism Ireland amongst others. “Ben’s appointment reflects our deep commitment to EMEA, where we continue to see strong momentum and increasing de
Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20405.6.2025 17:22:00 CEST | Press release
All SAP software licensees can now easily extend the useful life and maximize the full value of their current, proven and stable mission-critical systems and enjoy total maintenance savings of up to 90% without the requirement of a costly and risky migration to S/4HANA on RISE Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it has extended full support coverage for all SAP ECC 6.0 and S/4HANA releases through 2040, without any need to complete a migration to S/4HANA on RISE as required by SAP for clients who want to remain on SAP’s Annual Support and receive full support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605581964/en/ Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 2040 Rimini S
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform5.6.2025 16:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice® fully human antibody platform family. It underscores the continued advancement of Biocytogen’s comprehensive global patent strategy and highlights the innovation and international recognition of the company’s proprietary technologies. RenMab™ mice are a core member of Biocytogen’s independently developed RenMice® fully human antibody discovery platform family. Using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts.
Pink Bows Foundation Expands Showstop® Procedure Training and Certification Across Europe5.6.2025 16:00:00 CEST | Press release
Denmark’s Roskilde Festival hosts two days of Showstop Procedure training, 25 years after 9 tragic deaths Pink Bows Foundation (“organization” or “Pink Bows”) announced today another milestone - its global expansion - growing its impact with the successful delivery of two additional accredited Showstop® Procedure courses hosted by Denmark’s Roskilde Festival and attended by Paleo Festival and Engage Festival, among other event organizers and managers across Europe. Other sold-out training sessions took place in Dublin and Glasgow, with further courses to be announced for Fall 2025. “Never stop learning and improving. I believe that we have a good system for stopping a show at Roskilde Festival and RFX. We still hosted a course on Showstop procedure today on behalf of Pink Bows Foundation,” said Morton Therkilsden, Director of Safety, Roskilde Festival. Since its launch in Houston, Texas in March 2025, Pink Bows has trained 200 event professionals across the US, UK, Ireland and Denmark.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom